MedTrace Logo

EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

NCT02802592 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

Conditions

  • Cardiac Surgery-CABG
  • Cardiac Valve Replacement

Interventions

DRUG

Epogen

1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm

DRUG

Normal Saline

1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm

Sponsors & Collaborators

Principal Investigators

  • Keith A. Horvath, MD · Johns Hopkins Community Physicians

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-06-15
Completion
2017-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02802592 on ClinicalTrials.gov